title: Saphenous vein graft patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy. Results of a Veterans Administration Cooperative Study.
abstract: To determine whether antiplatelet therapies improve saphenous vein graft patency after coronary artery bypass grafting, we compared 1) aspirin (325 mg once daily), 2) aspirin (325 mg three times daily), 3) aspirin and dipyridamole (325 mg and 75 mg, respectively, three times daily), 4) sulfinpyrazone (267 mg three times daily), and 5) placebo (three times daily). Therapy with dipyridamole and sulfinpyrazone was started 48 hours before bypass graft surgery, and aspirin treatment was begun 12 hours before surgery as a single 325-mg dose. Postoperative treatment was started 6 hours after surgery and continued for 1 year. Graft patency data were obtained early (median, 9 days) and late (median, 367 days) after surgery. The early graft occlusion rate was decreased with all aspirin treatment regimens compared with that of the placebo regimen. At 1 year, in 406 patients with 1,315 grafts, the graft occlusion rate in all of the aspirin groups combined was 15.8% compared with 22.6% for the placebo group (p = 0.029). The patients taking aspirin once daily had a lower occlusion rate (13.2%) compared with the patients receiving placebo (p = 0.050). At 1 year, in the vein grafts placed to vessels less than or equal to 2.0 mm in diameter (804 distal sites), the graft occlusion rate in all of the aspirin groups was 20.1% compared with 32.3% for the placebo group (p = 0.008). In the vein grafts placed to vessels greater than 2.0 mm in diameter (511 distal sites), there was no difference in the occlusion rates between aspirin and the placebo group at 1 year (8.7% vs. 9.0%, p = 0.918).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Cardiology 111C, Veterans Administration Medical Center, Tucson, AZ 85723.
authors.forename: S
authors.initials: S
authors.lastname: Goldman
authors.forename: J
authors.initials: J
authors.lastname: Copeland
authors.forename: T
authors.initials: T
authors.lastname: Moritz
authors.forename: W
authors.initials: W
authors.lastname: Henderson
authors.forename: K
authors.initials: K
authors.lastname: Zadina
authors.forename: T
authors.initials: T
authors.lastname: Ovitt
authors.forename: J
authors.initials: J
authors.lastname: Doherty
authors.forename: R
authors.initials: R
authors.lastname: Read
authors.forename: E
authors.initials: E
authors.lastname: Chesler
authors.forename: Y
authors.initials: Y
authors.lastname: Sako
mesh_terms: D001241:Aspirin / Q000627:therapeutic use; D001026:Coronary Artery Bypass; D004176:Dipyridamole / Q000627:therapeutic use; D004311:Double-Blind Method; D006083:Graft Occlusion, Vascular / Q000517:prevention & control*; D006801:Humans; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012501:Saphenous Vein / Q000637:transplantation*; D013442:Sulfinpyrazone / Q000627:therapeutic use; D013997:Time Factors; D014654:Vascular Patency
chemical_list: D010975:Platelet Aggregation Inhibitors; D004176:Dipyridamole; D001241:Aspirin; D013442:Sulfinpyrazone